Shuren On US vs EU: FDA Strikes The Right Regulatory Balance
This article was originally published in SRA
While the medtech industry has often complained about how much longer it takes to get devices into the US compared with Europe, Jeff Shuren, director of the US FDA's device center thinks the agency has struck the right regulatory balance between public safety and an environment to allow innovation.
You may also be interested in...
While there are still a few months to go before the US FDA's Center for Devices and Radiological Health closes its customer service survey, the initial results look to be trending in the agency's favor. With almost nine-in-ten respondents giving a positive review, the results support the agency's efforts to improve customer service.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.